Synonyms: GSK286
Compound class:
Synthetic organic
Comment: GSK2556286 is a substituted 4-aryloxypiperidine identified from a screen of compounds that inhibit intracellular growth of Mycobacterium tuberculosis in human macrophage-like differentiated monocytes (THP-1 cell line) [2]. It has a novel cholesterol-dependent mechanism of action, with recent studies establishing it as an agonist of mycobacterial Rv1625c, a membrane-bound adenylyl cyclase [1-2]. GSK2556286 is under clinical development as a potential treatment for tuberculosis (TB).
|
|
No information available. |
Summary of Clinical Use |
A first-in-human safety, tolerability and pharmacokinetics study, evaluating GSK2556286 in healthy adult participants, began in October 2020 (NCT04472897). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04472897 | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2556286 in Healthy Adult Participants | Phase 1 Interventional | GlaxoSmithKline |